Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
It's making a major acquisition to beef up a key area of its pipeline. 
Via The Motley Fool
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)  
Via Benzinga
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Is AbbVie Stock a Buy Now?
AbbVie's business could soon become more diversified. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
The 3 Best Cheap Stocks to Buy in December
Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. 
Via InvestorPlace
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
From ImmunoGen Inc.
Via Business Wire
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
The big drugmaker went on a holiday shopping spree. 
Via The Motley Fool
Market Movers: Why Big Players Are Investing Millions in These 3 Stocks
In investing, certain stocks catch the discerning eye of big players, drawing in substantial investments. 
Via InvestorPlace
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days. 
Via The Motley Fool
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93. 
Via Investor's Business Daily
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the... 
Via Benzinga
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch
The Russell 2000 index comprises small-cap companies, exposing investors to small organizations. Consider buying these Russell 2000 stocks. 
Via InvestorPlace
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
From ImmunoGen, Inc.
Via Business Wire
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $ 
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Why Abbvie Stock Popped Today
The company announces a major deal worth over $10 billion. 
Via The Motley Fool
Nasdaq Falls Over 100 Points; Cracker Barrel Shares Slide After Q1 Results
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up 0.88% to 35,742.35 while the NASDAQ fell 0.79% to 14,145.17. The... 
Via Benzinga
Topics Stocks
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Crude Oil Falls Sharply; Kroger Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded up 0.85% to 35,729.88 while the NASDAQ fell 0.71% to 14,156.60. The S&P... 
Via Benzinga
Topics Stocks
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)... 
Via Benzinga
Why Is Soligenix (SNGX) Stock Up 285% Today?
Soligenix stock is rising higher on Thursday with heavy trading of SNGX shares after getting FDA approval for a Phase 2 clinical trial. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.